性结肠炎的双重生物疗法与可吸收的皮肤性性
Hae Chan Lee1, Yiyoung Kwon1, Eun Sil Kim1
1Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Annals of dermatology
|October 19, 2023
概括
本案例研究详细介绍了使用双生物制剂成功治疗性结肠炎 (UC) 中的皮皮性性结肠炎. 这种方法在单个药物失败时,战略地针对皮肤和肠道症状.
科学领域:
- 胃肠病学 胃肠病学
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
背景情况:
- 皮肤质性是性结肠炎 (UC) 的罕见肠外表现.
- 包括类固醇,免疫抑制剂和单一生物药物 (infliximab,golimumab, vedolizumab) 在内的常规治疗对患有复发性UC和pyoderma gangrenosum的患者无效.
- 这一案例凸显了UC中耐火性胃肠道和皮肤病症状管理的挑战.
研究的目的:
- 报告在韩国的一名性结肠炎患者中首次成功使用双重生物药物治疗皮肤炎.
- 为了证明一种新的治疗策略,用于难以治疗的皮肤和UC的肠道表现.
- 探索有针对性的双重生物治疗在管理复杂的UC病例中的潜力.
主要方法:
- 一名26岁的男性患者患有复发性性结肠炎和新发育的皮肤性性的治疗.
- 治疗涉及双重生物药物的组合,即韦多利祖马布和因弗利西马布.
- 根据每个生物制剂的独特作用机制,以针对特定症状进行战略性治疗.
主要成果:
- 双重生物疗法成功地解决了皮肤病变的皮肤病变和性结肠炎症状.
- 这种治疗方法在先前使用类固醇,免疫抑制剂和单一生物药物的单一疗法失败的情况下证明是有效的.
- 韦多利祖马布和因弗力西马布的战略应用在管理患者复杂病情方面表现出了协同效应.
结论:
- 与vedolizumab和infliximab的双重生物疗法代表了在性结肠炎患者中治疗耐火性皮肤病的有希望和有效的策略.
- 基于其作用机制的生物药物的有针对性的应用可以克服复杂UC病例的治疗耐药性.
- 这一案例为治疗炎症性肠病严重肠外表现的双重生物使用创造了先例.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
149
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
149
Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
Inflammatory Bowel Disease V: Surgical Management
149
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
149
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
122
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148


